Scientific innovations in immunotherapy are converging to create more scalable and precise treatments for HIV and cancer, with new strategies aiming to engineer a patient's immune cells inside their own body.
One of the most significant shifts is the move toward generating CAR T cells in vivo, or inside the patient. Currently, creating these engineered immune cells is a complex, expensive process requiring a patient's cells to be sent to an external lab for modification before being reinfused. Researchers are now developing methods to perform this engineering internally using engineered nanoparticles, tiny delivery vehicles that can carry genetic instructions directly to T cells in the bloodstream. This approach could transform CAR T therapy from a bespoke hospital procedure into a more widely deployable treatment. A specific research project led by Drs. Rachel Rutishauser and Brad Jones is applying this in vivo strategy to target HIV-infected cells, borrowing from advances in cancer to pursue a scalable intervention for HIV.
Alongside this, personalized mRNA vaccination is demonstrating clinical promise. In the KEYNOTE-942 trial, an individualized mRNA neoantigen vaccine combined with a checkpoint inhibitor showed improved outcomes for patients with high-risk melanoma after surgery. The technologies developed for these cancer vaccines, such as rapid tumor sequencing and sensitive immune monitoring, are directly beneficial for HIV research. For example, a separate initiative led by Drs. Sharon Lewin and Thumbi Ndung'u is developing lipid nanoparticles to deliver mRNA payloads specifically to T cells to reverse HIV latency, with a design attentive to global viral diversity.
Further progress in HIV research focuses on leveraging natural immune responses. Clinical trials are testing combinations of broadly neutralizing antibodies (bNAbs), lab-made antibodies that can block many HIV strains, to prevent viral escape. Simultaneously, vaccine researchers are making headway with germline targeting, a strategy that uses precisely designed vaccines to stimulate the rare immune cells capable of eventually producing bNAbs. Early human trials have successfully primed these starter cells, with the next major step being to guide this early response into broad, protective immunity through sequenced booster shots.
While no single approach guarantees an immediate cure, the collective progress represents a powerful trend. Older therapeutic platforms are becoming more testable and reproducible, and the cross-pollination of ideas between HIV and cancer research is accelerating the development of interventions that are not only effective but also practical for widespread use. The coming years are expected to yield crucial human data, particularly on the safety and durability of in vivo engineering, moving these sophisticated strategies closer to the patients who need them.